Literature DB >> 32576448

TFE3 Gene Rearrangement in Perivascular Epithelioid Cell Neoplasm (PEComa) of the Genitourinary Tract.

Margherita Vannucchi1, Andrea Minervini2, Matteo Salvi2, Rodolfo Montironi3, Maria Rosaria Raspollini4.   

Abstract

Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms with unpredictable behavior. They are characterized by epithelioid cells, which stain with melanocytic markers, associated with spindle cells reactive for smooth muscle markers. PEComas may be sporadic or associated with the tuberous sclerosis complex, with mutations affecting mostly tuberous sclerosis complex (TSC) 2 and less frequently TSC1 genes. More recently a subtype of PEComa harboring TFE3 gene rearrangement, mutually exclusive with TSC complex mutations, has been identified. The bladder and the other genitourinary tract organs are an infrequent site of origin; to date, only 3 cases of primitive bladder PEComas, 1 prostatic PEComa, and 2 epithelioid angiomyolipomas of the kidney with TFE3 rearrangement have been described in literature. We report a bladder PEComa case with Xp11 rearrangement in a patient who previously had undergone chemotherapy for chronic lymphatic leukemia. We assessed the meaning of the presence of TFE3 rearrangement in genitourinary tract PEComas and the possible correlation of these uncommon lesions with previous chemotherapy. A better understanding of this entity's genetics may help suggest appropriate targeted therapy, which is still lacking in genitourinary tract PEComas.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Folpe criteria; Outcome; PEComa of the bladder; Previous chemotherapy; TFE3 translocation

Mesh:

Substances:

Year:  2020        PMID: 32576448     DOI: 10.1016/j.clgc.2020.04.004

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  1 in total

Review 1.  TFE3-associated perivascular epithelioid cell tumor with complete response to mTOR inhibitor therapy: report of first case and literature review.

Authors:  Roli Purwar; Kishan Soni; Mridula Shukla; Ashish Verma; Tarun Kumar; Manoj Pandey
Journal:  World J Surg Oncol       Date:  2022-03-01       Impact factor: 2.754

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.